Colette Ngozi Owens MD
Hematologic Oncology
Assistant Attending at Memorial Sloan Kettering Cancer Center
480 Red Hill RoadMiddletown, NJ 07748
Overview of Dr. Owens
Dr. Colette Owens is an oncologist in Middletown, NJ and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Hackensack Meridian Health Riverview Medical Center, and Memorial Sloan Kettering Monmouth. She received her medical degree from Rutgers Robert Wood Johnson Medical School and has been in practice 16 years. She is one of 526 doctors at Memorial Sloan Kettering Cancer Center and one of 46 doctors at Hackensack Meridian Health Riverview Medical Center who specialize in Oncology. She has more than 30 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2010 - 2013
Rutgers Robert Wood Johnson Medical SchoolClass of 2010
Certifications & Licensure
FL State Medical License 2022 - Present
NJ State Medical License 2016 - 2027
NY State Medical License 2012 - 2027
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MyMSK, Memorial Sloan Kettering, 2017
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2017
Publications & Presentations
PubMed
- Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental ...Erel Joffe, Anita Kumar, Joseph M Tuscano, Alison J Moskowitz, Colette Owens
Cancers. 2026-01-16 - 1 citationsTwo decades of single-institution data reveal rare longterm survivors of relapsed/refractory Burkitt lymphoma.Rabeya Molla, Kurt Bantilan, Ellin Berman, Philip Caron, Lorenzo Falchi
Haematologica. 2026-01-01 - 1 citationsNovel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.Raphael Steiner, Liana Nikolaenko, Ranjit Nair, Venkatraman Seshan, Swetha Kambhampati Thiruvengadam
Blood Advances. 2025-11-11
Abstracts/Posters
- Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin LymphomaColette Owens, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...Colette Owens, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...Colette Owens, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Challenges of Managing Older Patients with Diffuse Large B-cell LymphomaSeptember 10th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
